Temasek et al To Exit from Cell Therapies Developer, Gracell
27 Dec 2023
US$ 19.00
Temasek Holdings (Pte) Ltd, Vivo Capital LLC (Vivo) and OrbiMed Advisors LLC (OrbiMed) will conclude their investment...
Related Publications
Subscribers’ Weekly...
Listen to Australia/New Zealand Investments (Subscribers' Weekly 06 Jun 2025)...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.